PubMed

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Kjems LL, Holst JJ, Vølund A, Madsbad S.

Diabetes. 2003 Feb;52(2):380-6.PMID: 12540611 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.

Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.

Diabetes. 1998 Aug;47(8):1259-65.PMID: 9703326 [PubMed - indexed for MEDLINE]Related articlesFree article

GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.

Brandt A, Katschinski M, Arnold R, Polonsky KS, Göke B, Byrne MM.

Am J Physiol Endocrinol Metab. 2001 Aug;281(2):E242-7.PMID: 11440899 [PubMed - indexed for MEDLINE]Related articlesFree article

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB.

Diabetes. 2003 Jul;52(7):1786-91.PMID: 12829647 [PubMed - indexed for MEDLINE]Related articlesFree article

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.

Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic S, Giacca A.

Diabetes. 1999 May;48(5):1045-53.PMID: 10331409 [PubMed - indexed for MEDLINE]Related articlesFree article

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.

Ahrén B, Holst JJ, Mari A.

Diabetes Care. 2003 Oct;26(10):2860-4.PMID: 14514592 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.

Diabetes. 1998 Jan;47(1):45-9.PMID: 9421373 [PubMed - indexed for MEDLINE]Related articles

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.

Toft-Nielsen MB, Madsbad S, Holst JJ.

J Clin Endocrinol Metab. 2001 Aug;86(8):3853-60.PMID: 11502823 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

Diabetes. 2001 Apr;50(4):776-84.PMID: 11289042 [PubMed - indexed for MEDLINE]Related articlesFree article

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabetologia. 2008 Apr;51(4):632-40. Epub 2008 Feb 22.PMID: 18292985 [PubMed - indexed for MEDLINE]Related articles

Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.

Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M.

Diabetologia. 2000 Jul;43(7):852-8.PMID: 10952457 [PubMed - indexed for MEDLINE]Related articles

Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.

Greenbaum CJ, Prigeon RL, D'Alessio DA.

Diabetes. 2002 Apr;51(4):951-7.PMID: 11916912 [PubMed - indexed for MEDLINE]Related articlesFree article

No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Diabet Med. 2001 Feb;18(2):144-9.PMID: 11251679 [PubMed - indexed for MEDLINE]Related articles

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.

Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.PMID: 9374685 [PubMed - indexed for MEDLINE]Related articlesFree article